Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.
Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A. Trillsch F, et al. Among authors: kommoss f. Ann Oncol. 2014 Jul;25(7):1320-1327. doi: 10.1093/annonc/mdu119. Epub 2014 Mar 11. Ann Oncol. 2014. PMID: 24618151 Free article.
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. du Bois A, et al. Among authors: kommoss f, kommoss s. Eur J Cancer. 2013 May;49(8):1905-14. doi: 10.1016/j.ejca.2013.01.035. Epub 2013 Mar 13. Eur J Cancer. 2013. PMID: 23490647
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators. Fotopoulou C, et al. Among authors: kommoss f, kommoss s. Int J Gynecol Cancer. 2015 Sep;25(7):1248-52. doi: 10.1097/IGC.0000000000000476. Int J Gynecol Cancer. 2015. PMID: 25978292
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study.
Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A. Trillsch F, et al. Among authors: kommoss f, kommoss s. Br J Cancer. 2015 Feb 17;112(4):660-6. doi: 10.1038/bjc.2014.648. Epub 2015 Jan 6. Br J Cancer. 2015. PMID: 25562434 Free PMC article. Clinical Trial.
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J, Du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Pfisterer J, et al. Among authors: kommoss f. Int J Gynecol Cancer. 2009 Jan;19(1):109-15. doi: 10.1111/IGC.0b013e3181991a7c. Int J Gynecol Cancer. 2009. PMID: 19258951 Clinical Trial.
Borderline tumors of the ovary: clinical course and prognostic factors.
Ewald-Riegler N, du Bois O, Fisseler-Eckhoff A, Kommoss F, Harter P, Traut A, Hils R, du Bois A. Ewald-Riegler N, et al. Among authors: kommoss f. Onkologie. 2012;35(1-2):28-33. doi: 10.1159/000336140. Epub 2012 Jan 23. Onkologie. 2012. PMID: 22310342
Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S. du Bois A, et al. Among authors: kommoss f, kommoss s. Eur J Cancer. 2016 Sep;65:192-193. doi: 10.1016/j.ejca.2016.06.014. Epub 2016 Jul 25. Eur J Cancer. 2016. PMID: 27468640 No abstract available.
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J. Kommoss S, et al. Among authors: kommoss f. Clin Cancer Res. 2017 Jul 15;23(14):3794-3801. doi: 10.1158/1078-0432.CCR-16-2196. Epub 2017 Feb 3. Clin Cancer Res. 2017. PMID: 28159814 Free PMC article. Clinical Trial.
185 results